Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Income from Continuing Operations (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Income from Continuing Operations for 6 consecutive years, with 22977000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 33.82% to 22977000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 121710000.0, a 3.72% increase, with the full-year FY2025 number at 129766000.0, down 2.66% from a year prior.
  • Income from Continuing Operations was 22977000.0 for Q4 2025 at TScan Therapeutics, up from 34127000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 7912000.0 in Q1 2021 to a low of 34719000.0 in Q4 2024.
  • A 5-year average of 21520888.89 and a median of 21088000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 120.91% in 2021, then surged 33.82% in 2025.
  • TScan Therapeutics' Income from Continuing Operations stood at 14200000.0 in 2021, then crashed by 31.85% to 18723000.0 in 2022, then decreased by 4.75% to 19613000.0 in 2023, then plummeted by 77.02% to 34719000.0 in 2024, then soared by 33.82% to 22977000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Income from Continuing Operations are 22977000.0 (Q4 2025), 34127000.0 (Q1 2025), and 34719000.0 (Q4 2024).